drugset

drugset / Trial / NCT00478959

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

NCT00478959 ↗

Phase 2 Completed 30 enrolled University Health Network, Toronto Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label Phase II study evaluating the activity of Lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma.

Timeline

Start: 2006-12
Primary completion: 2014-06
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Indications